Pharmaceutics (May 2021)

Anti-Tumor and Anti-Inflammatory Activity In Vivo of <i>Apodanthera congestiflora</i> Cogn. (Cucurbitaceae)

  • Geovana F. G. Silvestre,
  • Renally P. Lucena,
  • Genil D. Oliveira,
  • Helimarcos N. Pereira,
  • Jhonatta A. B. Dias,
  • Ivone A. Souza,
  • Harley S. Alves

DOI
https://doi.org/10.3390/pharmaceutics13050743
Journal volume & issue
Vol. 13, no. 5
p. 743

Abstract

Read online

This work aimed to carry out a study of Apodanthera congestiflora by investigating its chemical composition and pharmacological potential. From the dichloromethane phase (Dic-Ac) of the A. congestiflora stems, three compounds were identified: cayaponoside C5b (Ac-1), cabenoside C (Ac-2) and fevicordin C2 glucoside (Ac-3), being last identified for the first time as a natural product. These compounds were obtained by chromatographic methods and their structures were elucidated by means of spectroscopic analysis of IR, MS and NMR. In the quantification of Dic-Ac, it was possible to observe the presence of 7% of cayaponoside C5b. Dic-Ac showed significant toxicity for in vivo tests, with macroscopic and biochemical changes. The anti-inflammatory activity of Dic-Ac was investigated using the paw edema model. A decrease in inflammatory signs was observed in the first 5 h and the most effective dose in reducing edema with was 7.5 mg kg−1 (66.6%). Anti-tumor activity of Dic-Ac was evaluated by Ehrlich’s carcinoma model, which showed inhibition rate of 78.46% at 15 mg kg−1 dosage. The phytochemical investigation, together with the biological tests carried out in this study, demonstrated that A. congestiflora is a promising species in the search for therapeutics, since it contains substances with high pharmacological potential in its composition.

Keywords